BioSpace News Archive

- SPRAVATO® is the first and only approved antidepressant medication shown to begin improving depressive symptoms with the first dose in this challenging to treat patient population - Approval is based on Phase 3 data showing SPRAVATO® reduced depressive symptoms in as little as four hours in some patients, with symptom improvement maintained through the four-week treatment period [03-August-2020]

TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 3:30 p.m. ET. A live webcast of Intellia’s presentation will be accessible through the Events and Presentations page of the Investors & Media section of the co

QIDP Designation Allows for FDA Priority Review, Fast-Track Designation, and an Additional Five Years of Market Exclusivity for SBG003

Study is evaluating ALRN-6924 to protect against chemotherapy-induced bone marrow toxicities in patients with p53-mutated small cell lung cancer (SCLC) treated with topotecan Previously reported positive interim data from dose optimization part of study demonstrated 0.3 mg/kg dose of ALRN-6924, now being evaluated in expansion cohort, resulted in most robust chemoprotective effects

Cytovia Therapeutics, Inc (“Cytovia”), an emerging biopharmaceutical company developing natural killer (NK) immunotherapies for cancer, today announces that it has acquired worldwide rights from CytoImmune Therapeutics for its novel EGFR Dual-targeting CAR to be used for NK cell therapy. Cytovia will conduct and finance all future development and will apply the EGFR Dual-targeting CAR to its iPSC CAR NK technology. CytoImmune wil

Sysmex America, Inc., a leading diagnostic company offering hematology, urinalysis, information systems and flow cytometry testing solutions for optimal clinical laboratory performance, announced the availability of its new clinical software application, Caresphere™ Workflow Solution.

Vopec Pharmaceuticals Pvt Ltd ( https://www.vopecpharma.com/ ) today announces it has completed one of India’s first COVID-19 clinical trials on an herbal, Siddha formulation, Amrta Karuna. The clinical trial registered with the Indian Council for Medical Research

Company announces database lock and plans to report top-line data from global Phase 3 PRO2TECT program of vadadustat for treatment of anemia due to chronic kidney disease in adult patients not on dialysis

Karius, the world leader in liquid biopsy for infectious diseases, announced today active enrollment in a multicenter, prospective study that will evaluate the diagnostic value of the Karius ® Test for pneumonia in immunocompromised adult patients including those with hematological cancers. The Karius Test is a non-invasive bloo